Antimicrobial Stewardship is complex
As hospitals, healthcare providers, and society find themselves entering a new phase of the COVID-19 pandemic, renewed attention is being focused on the importance of antimicrobial stewardship in reducing the development of antimicrobial resistance. Recent regulatory changes provide meaningful impetus for health-system pharmacists to evaluate the effectiveness of their antimicrobial stewardship (AMS) program. These regulatory changes include:
Updated Joint Commission medication management standards on antimicrobial stewardship in 2023, and
New requirements on Antimicrobial Use and Resistance (AUR) reporting to National Healthcare Safety Network (NHSN) to satisfy the Public Health and Clinical Data Exchange objective of the Medicare Promoting Interoperability program in 2024.
In this new series of articles from Wolters Kluwer, we aim to deliver concise, practical, and actionable items as a resource to busy clinicians to help them assess their AMS programs and identify opportunities for improvement, and most importantly succeed in meeting any accreditation and regulatory requirements.
'Back to AMS Basics' series, highlights include:
- Structuring your AMS program for success
- AMS program scope and responsibilities
- Multi-disciplinary participation to ensure success
- Measuring antimicrobial use
- Documenting antimicrobial use and intent
- Preauthorization and prospective feedback
- Using evidence-based guidelines to improve prescribing
- Data analysis in AMS
- Performance improvement in AMS
- Using technology to improve AMS program effectiveness